First Tracks Biotherapeutics, Inc.
TRAXNext catalyst
Phase 3 — zipalertinib
Get an email about TRAX's next catalysts
Track First Tracks Biotherapeutics (TRAX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 2 past
Phase 3 — zipalertinib
For cancer. Taiho Pharmaceutical and Cullinan Therapeutics' zipalertinib successfully completed a Phase 3 trial and is currently under FDA review with a decision expected by February 2027, positioning the asset for first-line cancer competition.
SourceHow TRAX's past catalysts played out
Market Overview
Stock performance and key metrics
No drugs found in this phase.
cancer
2 drugs in this indication
advanced GEP-NETs
1 drug in this indication
stem cell transplant preparation
1 drug in this indication
First-line unresectable hepatocellular carcinoma (HCC)
1 drug in this indication
First-line consolidation therapy in MRD-positive large B-cell lymphoma
1 drug in this indication
Alexander disease in pediatric and adult patients
1 drug in this indication
Alexander disease
1 drug in this indication
spinal cord injuries
1 drug in this indication
cholangiocarcinoma with acquired FGFR inhibitor resistance
1 drug in this indication
BCL (B-cell lymphoma)
1 drug in this indication
early-onset disc problems
1 drug in this indication
relapsed/refractory multiple myeloma
1 drug in this indication
weight loss
1 drug in this indication
senescent cell accumulation, aging-related metabolic dysfunction
1 drug in this indication
hematologic malignancy (follicular lymphoma)
1 drug in this indication
soft tissue sarcoma
1 drug in this indication
Pulmonary heart valve for pediatric patients with congenital pulmonary valve disease
1 drug in this indication
symptomatic HFpEF (heart failure with preserved ejection fraction)
1 drug in this indication
dermatomyositis in adults
1 drug in this indication
Recurrent atypical teratoid/rhabdoid tumor (CNS tumor)
1 drug in this indication
Recurrent urinary tract infections (UTIs)
1 drug in this indication
pancreatic cancer
1 drug in this indication
Mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) in pediatric patients
1 drug in this indication
Local anesthesia, nerve blocks, pain management
1 drug in this indication
Recurrent respiratory papillomatosis (RRP) in adults
1 drug in this indication
Sickle cell disease
1 drug in this indication
PRKAG2 syndrome
1 drug in this indication
First-line metastatic triple-negative breast cancer
1 drug in this indication
nonsense mutation Alport syndrome
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
When is First Tracks Biotherapeutics, Inc.'s next FDA catalyst?→
First Tracks Biotherapeutics, Inc.'s (TRAX) next tracked catalyst is a Phase 3 readout expected Feb 28, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TRAX biotech catalysts?→
Add TRAX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow First Tracks Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
